STAMFORD, Conn.--(BUSINESS WIRE)--SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that Alan Fuhrman has been appointed to its Board of Directors. Mr. Fuhrman is an experienced finance executive with a successful track record guiding the growth of innovative pharmaceutical and biotechnology companies. He currently serves as the Chief Financial Officer (CFO) of Amplyx Pharmaceuticals, Inc., a biotechnology company focused on developing novel products for life-threatening infections. Mr. Fuhrman is currently a member of the Board of Directors of Checkmate Pharmaceuticals and previously served on the Board of Directors and as Chair of the Audit Committee of Loxo Oncology until its sale to Eli Lilly in the first quarter of 2019.
Prior to joining Amplyx, Mr. Fuhrman served as CFO of Mirna Therapeutics, a clinical-stage microRNA company that merged with Synlogic in August 2017. He also previously served as CFO of Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in 2014. Earlier in his career, Mr. Fuhrman practiced as a certified public accountant with Coopers & Lybrand. Mr. Fuhrman received a B.S. in both Business Administration and Agricultural Economics from Montana State University.
“We are delighted to welcome Alan to the SpringWorks Board of Directors. His financial leadership and experience will further strengthen our board and guide the company’s growth as we pursue a transition to a publicly traded company,” said Daniel S. Lynch, Chairman of SpringWorks.
Saqib Islam, Chief Executive Officer of SpringWorks added, “Alan is a great addition to our board during this exciting phase of the company’s evolution. We are focused on building a leading targeted oncology company and I am pleased that Alan will join us in our mission to change the lives of people living with severe rare diseases and cancer.”
“SpringWorks is a unique company with an honorable purpose to develop and deliver life-changing medicines for underserved patient communities,” said Mr. Fuhrman. “I am excited to join the SpringWorks Board and look forward to contributing to the company’s future growth and success.”
Mr. Fuhrman will also serve as chair of the Audit Committee.
About SpringWorks Therapeutics
At SpringWorks, a clinical-stage biopharmaceutical company, we are driven to develop life-changing medicines for patients with severe rare diseases and cancer. Since our launch in 2017, we have worked to identify and advance promising science, beginning with our licensed clinical therapies from Pfizer Inc. We pioneer efficient pathways for drug development, leveraging shared-value partnerships with patient advocacy groups, innovators in industry and academia, and investors so that together, we can unlock the potential of science and bring new therapies to underserved patients. Nirogacestat, our gamma secretase inhibitor for the treatment of desmoid tumors, is currently in a Phase 3 clinical trial (DeFi Trial), and SpringWorks expects to initiate a Phase 2b clinical trial of mirdametinib, our MEK 1/2 inhibitor for neurofibromatosis type 1 patients with plexiform neurofibromas, in the third quarter of 2019 (ReNeu Trial). Both nirogacestat and mirdametinib also hold promise as backbones for combination therapies to treat metastatic cancers. At SpringWorks, we ignite the power of promising science to unleash new possibilities for patients. For more information, please visit www.springworkstx.com.